<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>Resiquimod</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>Resiquimod</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/thumb/6/6b/Resiquimod.svg/250px-Resiquimod.svg.png"/></li>
<li>Availability in Oral Form</li>
<ul>
<li>Research indicates that Resiquimod is not currently available in oral form for general use. While it has been investigated in clinical trials for oral administration, particularly for chronic hepatitis C virus (HCV) infection, these studies did not lead to approval for oral use. For instance, a phase IIa study published in 2007 explored oral Resiquimod at doses of 0.01 mg/kg and 0.02 mg/kg twice weekly for 4 weeks, but it was associated with adverse effects similar to interferon-alpha, such as fever and lymphopenia (<a href="https://drugs.ncats.io/drug/V3DMU7PVXF">source</a>).</li>
<li>Regulatory data from the FDA's Orphan Drug Designations page, updated as of recent reports, shows Resiquimod has a designation for treating cutaneous T-cell lymphoma since May 24, 2017, but it is not FDA-approved for this indication, and the form is not specified as oral (<a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">source</a>), it seems unlikely that oral Resiquimod is available for public use as of June 29, 2025.</li>
</ul>
<li>Clinical Trials and Safety Concerns</li>
<ul>
<li>The clinical trials for oral Resiquimod, particularly for HCV, provide insight into its safety profile. The 2007 study mentioned above noted that while a 0.01 mg/kg dose was tolerated, the 0.02 mg/kg dose led to severe adverse events, including systemic cytokine induction symptoms like fever, headache, and shivering, leading to discontinuation in some cases (<a href="https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/resiquimod">source</a>). These findings suggest that oral administration is not pursued further due to safety concerns.</li>
<li>For other conditions, such as genital herpes, phase III trials of topical Resiquimod were suspended due to lack of efficacy, and there is no recent evidence of renewed interest in oral forms (<a href="https://www.sciencedirect.com/topics/immunology-and-microbiology/resiquimod">source</a>). The evidence leans toward oral Resiquimod being unsafe for general use, especially given the lack of approval and the adverse effects observed in trials.</li>
</ul>
<li>Recommendations for Use</li>
<ul>
<li>Given the evidence, it is not recommended to take Resiquimod orally outside of controlled clinical trial settings. The adverse effects observed in trials, combined with the lack of approval, suggest potential risks that outweigh benefits for lay use. For medical advice, consulting a healthcare provider is essential, especially considering individual health conditions and the specific indications for Resiquimod.</li>
</ul>
<li>Resiquimod, also known as R-848, is an immune response modifier classified as a potent agonist for Toll-like receptors 7 and 8 (TLR7/TLR8). Its pharmacological profile and clinical applications have been extensively studied, particularly for antiviral and antitumor activities. This note provides a detailed examination of its pharmacological actions, pharmacokinetics, dosages, and safety profiles, based on available literature as of June 27, 2025.</li>
<li>Pharmacological Actions</li>
<li>Resiquimod's primary mechanism involves activating TLR7 and TLR8, which are endosomal pattern recognition receptors critical for antiviral immune responses. This activation triggers the MyD88-dependent signaling pathway, leading to the activation of transcription factors such as NF-κB and interferon regulatory factor (IRF). Consequently, it induces the upregulation of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and type I interferons (IFN-α), which are essential for enhancing innate and adaptive immunity.</li>
<li>Specific pharmacological actions include:</li>
<ul>
<li>Cytokine Induction: Resiquimod significantly increases levels of TNF-α, IL-6, IL-12, and IFN-α, as noted in studies on mouse bone marrow-derived macrophages and human peripheral blood mononuclear cells (<a href="https://www.selleckchem.com/products/resiquimod.html">source</a>).</li>
<li>Immune Cell Activation: It activates dendritic cells, macrophages, and other immune cells, promoting antigen presentation and T-cell activation, which is beneficial for antiviral and antitumor responses (<a href="https://www.invivogen.com/r848">source</a>).</li>
<li>Antiviral Activity: Demonstrated efficacy against viruses such as hepatitis C virus (HCV) and herpes simplex virus, with studies showing reduced viral loads in clinical trials (<a href="https://en.wikipedia.org/wiki/Resiquimod">source</a>).</li>
<li>Antitumor Activity: Used in treating cutaneous T-cell lymphoma and other skin cancers, with potential as an adjuvant in cancer immunotherapy, enhancing tumor-associated macrophage stimulation (<a href="https://pubmed.ncbi.nlm.nih.gov/17532523/">source</a>).</li>
</ul>
<li>Pharmacokinetics</li>
<li>Pharmacokinetic data for Resiquimod is limited, particularly for half-life and bioavailability, but available studies provide insights into its absorption and systemic exposure:</li>
<ul>
<li>Topical Application: Studies indicate low systemic absorption, with systemic exposure less than 1% of the applied dose in humans, assessed by urinary recovery, and approximately 8.5% in rats, as reported in a randomized, single-blind study (<a href="https://www.sciencedirect.com/topics/neuroscience/resiquimod">source</a>).</li>
<li>Oral Administration: In a phase IIa study for chronic HCV infection, oral doses of 0.01 mg/kg and 0.02 mg/kg resulted in mean maximum serum concentrations of 3.82 ± 1.47 ng/mL and 7.55 ± 4.17 ng/mL, respectively, administered twice weekly for 4 weeks (<a href="https://pubmed.ncbi.nlm.nih.gov/17532523/">source</a>). However, specific half-life and bioavailability data were not detailed in accessible literature, with moderate oral bioavailability suggested (26.5 ± 7.84%) in some references, though not universally confirmed.</li>
</ul>
<li>The lack of precise half-life data indicates a gap in current research, with estimates potentially ranging from 2-3 hours based on related studies, but this requires further validation.</li>
<li>Dosages</li>
<li>Dosage regimens vary by administration route and therapeutic intent:</li>
<ul>
<li>Topical Use: Commonly applied as a gel, with concentrations such as 0.01% for genital herpes and 0.03-0.06% for actinic keratosis (AK), covering up to 100 cm², with dosing frequencies adjusted based on tolerability (e.g., 3 times weekly, escalating to daily) (<a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/resiquimod">source</a>).</li>
<li>Oral Use: In the HCV study, doses of 0.01 mg/kg were tolerated, while 0.02 mg/kg led to increased adverse events, suggesting a minimum effective dose around 0.01 mg/kg and a maximum safe dose likely below 0.02 mg/kg, though exact ranges are not standardized (<a href="https://pubmed.ncbi.nlm.nih.gov/17532523/">source</a>).</li>
</ul>
<li>Safe Range, Minimum Effective Dose, and Maximum Safe Dose:</li>
<ul>
<li>Safe Range: Topical use appears safe with low systemic absorption, while oral use at 0.01 mg/kg is generally tolerated, with 0.02 mg/kg showing increased risk.</li>
<li>Minimum Effective Dose: Likely 0.01 mg/kg orally for systemic effects, and 0.01% gel topically for local effects.</li>
<li>Maximum Safe Dose: Oral administration at 0.02 mg/kg showed adverse effects, suggesting this as an upper limit, but precise maximum without high risks is unclear.</li>
</ul>
<li>LD50 and Danger Threshold:</li>
<ul>
<li>Specific LD50 values were not found, indicating a lack of comprehensive toxicity studies in public domains. For topical use, low systemic absorption suggests minimal risk of systemic toxicity, while oral use at higher doses (e.g., 0.02 mg/kg) is associated with systemic cytokine induction and adverse effects, potentially starting to become dangerous at doses exceeding this, though exact thresholds are not established.</li>
</ul>
<li>Detailed Safety and Toxicity Profile</li>
<li>Toxicity data is sparse, with literature emphasizing local reactions for topical use (e.g., erythema, induration) and systemic effects for oral use (e.g., fever, lymphopenia). The ResearchGate PDF notes that topical 0.01% gel is unlikely to cause systemic toxicity due to low absorption, while oral capsules cause systemic cytokine induction, suggesting potential toxicity at higher doses (<a href="https://www.researchgate.net/publication/233836670_Resiquimod_a_topical_drug_for_viral_skin_lesions_and_skin_cancer">source</a>). No LD50 values were identified, highlighting a research gap in systemic toxicity assessments.</li>
<li><table>
<tr>
<th>Parameter</th>
<th>Value</th>
<th>Route</th>
<th>Notes</th>
</tr>
<tr>
<td>Systemic Exposure (Topical)</td>
<td>&lt;1% of applied dose</td>
<td>Topical</td>
<td>Based on urinary recovery in humans</td>
</tr>
<tr>
<td>Absorption (Topical, Rats)</td>
<td>~8.5%</td>
<td>Topical</td>
<td>From animal studies</td>
</tr>
<tr>
<td>Cmax (Oral, 0.01 mg/kg)</td>
<td>3.82 ± 1.47 ng/mL</td>
<td>Oral</td>
<td>From HCV study</td>
</tr>
<tr>
<td>Cmax (Oral, 0.02 mg/kg)</td>
<td>7.55 ± 4.17 ng/mL</td>
<td>Oral</td>
<td>From HCV study</td>
</tr>
<tr>
<td>Bioavailability (Oral, Est.)</td>
<td>Moderate, 26.5 ± 7.84% (not confirmed)</td>
<td>Oral</td>
<td>Suggested, needs validation</td>
</tr>
</table></li>
<li><table>
<tr>
<th>Dosage Type</th>
<th>Dose Range</th>
<th>Safety Notes</th>
</tr>
<tr>
<td>Topical (Gel)</td>
<td>0.01-0.06%</td>
<td>Safe, low systemic absorption, local reactions</td>
</tr>
<tr>
<td>Oral (HCV Study)</td>
<td>0.01-0.02 mg/kg</td>
<td>0.01 mg/kg tolerated, 0.02 mg/kg adverse effects</td>
</tr>
</table></li>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main></body></html>